1033805-26-3

Basic information

• Product Name: (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol
• Synonyms: (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol;(S)-1-(4-chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol;(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethan-1-ol;Benzenemethanol, 4-chloro-2-(3-methyl-1H-pyrazol-1-yl)-α-(trifluoromethyl)-, (αR)-;(R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethan-1-ol;EOS-61311;(R)-1-[4-Chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethanol;(R)-1-[4-Chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethanol
• CAS NO: 1033805-26-3
• Molecular Formula: C12H10ClF3N2O
• Molecular Weight: 290.6688096
• Mol File: 1033805-26-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 393.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 11.44±0.14(Predicted)
• CAS DataBase Reference: (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol(1033805-26-3)
• EPA Substance Registry System: (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol(1033805-26-3)

Safety Data

• Hazardous Substances Data: 1033805-26-3(Hazardous Substances Data)

Usage

General Description

"(R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol" is a chemical compound with a molecular formula C13H11ClF3N3O. It is a chiral compound, meaning it has two enantiomers which are mirror images of each other. This chemical is a trifluoroethanol derivative, which is commonly used in organic synthesis and as a solvent for a variety of reactions. The presence of a chloro and a methyl-pyrazol-1-yl group in its structure makes it potentially useful in pharmaceutical research and development. Additionally, the trifluoroethanol group makes this compound a potentially valuable reagent in the synthesis of other complex organic molecules. (R)-1-(4-Chloro-2-(3-Methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol may have potential applications in medicinal chemistry, agrochemicals, and material science due to its unique structure and properties.

Upstream product

• 1125828-30-9 1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanone 
• 1996-29-8 1-bromo-4-chloro-2-fluorobenzene 
• 75-90-1 2,2,2-Trifluoroacetaldehyde 
• 1125828-26-3 1-(2-bromo-5-chlorophenyl)-3-methyl-1H-pyrazole 
• 1453-58-3 3-Methylpyrazole 
• 1033805-25-2 (R)-1-(2-bromo-4-chlorophenyl)-2,2,2-trifluoroethane-1-ol 

Downstream Products

• 1033805-27-4 (S)-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)-2-(tert-butoxycarbonylamino)propanoic acid 
• 1033805-28-5 (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)-phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid 

Relevant articles and documents

Development of an Enzymatic Process for the Synthesis of the Key Intermediate of Telotristat Ethyl

(R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethan-1-ol [(R)-2] is a key chiral intermediate in the synthesis of telotristat ethyl, an anti-carcinoid syndrome drug. However, the synthetic methods for (R)-2 mainly include chemical reductions, rarely involving biocatalysis or bioreduction until now. Here, we report a method for obtaining (R)-2 by biocatalytic reduction of corresponding prochiral acetophenone (1) with bulky o-substitution using recombinant Lactobacillus fermentum short-chain dehydrogenase/reductase 1 (LfSDR1) as a biocatalyst. Further engineering of LfSDR1 variants could access asymmetric reduction of 1 and yield (R)-2 with a >99% ee and a >99% conversion. In addition, through the test of different co-solvents and a series of initial substrate concentrations, substrate 1 with the concentration of 60 g/L can be completely converted into (R)-2 on a preparative scale (1.13 g, 3.93 mmol, 75.6% isolated yield) in 24 hours. This study presents an efficient enzymatic process for the biocatalytic synthesis of key chiral intermediate (R)-2 in the synthesis of telotristat ethyl. (Figure presented.).

Application of asymmetric 1,2-addition reaction in compounding of telotristat ethyl midbody

The invention provides a compounding method for a compound telotristat ethyl midbody as shown in formula (1). The method comprises the following steps: by taking a compound as shown in formula (2) as an initial raw material, performing grignard and asymmetric 1,2-addition reaction and finally acquiring the compound as shown in formula (1), thereby acquiring the telotristat ethyl midbody as shown in the specification. Compared with the prior art, the compounding method has the advantages that the telotristat ethyl midbody compounding process is simple and the compounding cost is low, the compounding method has the advantages that the compounding method is simple and feasible, the cost is low, the yield is higher, the product quality is high and the method is suitable for industrial production.

SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS

The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.